Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment

Authors

Richard Kim, H. Lee Moffitt Cancer Center & Research Institute
E. Gabriela Chiorean, University of Washington - Seattle Campus
Manik Amin, Washington University School of Medicine in St. Louis
Caio Max S. Rocha-Lima, Gibbs Cancer Center & Research Institute
Jitendra Gandhi, Associates in Oncology & Hematology, Chattanooga, TN
William P. Harris, University of Washington - Seattle Campus
Tao Song, Spectrum Pharmaceuticals Inc.
David Portnoy, West Cancer Center, Memphis, TN

Journal

British Journal of Cancer

Publication Date

2017

Inclusive Pages

1-6

Document Type

Open Access Publication

DOI

10.1038/bjc.2017.160

Rights and Permissions

Richard Kim, E Gabriela Chiorean, Manik Amin, Caio Max S Rocha-Lima, Jitendra Gandhi et al. (2017). Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. British Journal of Cancer. doi: 10.1038/bjc.2017.160. www.bjcancer.com Copyright 2017 Cancer Research UK From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ 11 July 2017 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Recommended Citation

Kim, Richard; Chiorean, E. Gabriela; Amin, Manik; Rocha-Lima, Caio Max S.; Gandhi, Jitendra; Harris, William P.; Song, Tao; and Portnoy, David, "Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment." British Journal of Cancer. 1-6. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5965